9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn’s-Like Microbiota Disturbances

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cystic fibrosis (CF) is a systemic genetic disease that leads to pulmonary and digestive disorders. In the majority of CF patients, the intestine is the site of chronic inflammation and microbiota disturbances. The link between gut inflammation and microbiota dysbiosis is still poorly understood. The main objective of this study was to assess gut microbiota composition in CF children depending on their intestinal inflammation. We collected fecal samples from 20 children with CF. Fecal calprotectin levels were measured and fecal microbiota was analyzed by 16S rRNA sequencing. We observed intestinal inflammation was associated with microbiota disturbances characterized mainly by increased abundances of Staphylococcus, Streptococcus, and Veillonella dispar, along with decreased abundances of Bacteroides, Bifidobacterium adolescentis, and Faecalibacterium prausnitzii. Those changes exhibited similarities with that of Crohn’s disease (CD), as evidenced by the elevated CD Microbial-Dysbiosis index that we applied for the first time in CF. Furthermore, the significant over-representation of Streptococcus in children with intestinal inflammation appears to be specific to CF and raises the issue of gut–lung axis involvement. Taken together, our results provide new arguments to link gut microbiota and intestinal inflammation in CF and suggest the key role of the gut–lung axis in the CF evolution.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Fungal microbiota dysbiosis in IBD

          Objective The bacterial intestinal microbiota plays major roles in human physiology and IBDs. Although some data suggest a role of the fungal microbiota in IBD pathogenesis, the available data are scarce. The aim of our study was to characterise the faecal fungal microbiota in patients with IBD. Design Bacterial and fungal composition of the faecal microbiota of 235 patients with IBD and 38 healthy subjects (HS) was determined using 16S and ITS2 sequencing, respectively. The obtained sequences were analysed using the Qiime pipeline to assess composition and diversity. Bacterial and fungal taxa associated with clinical parameters were identified using multivariate association with linear models. Correlation between bacterial and fungal microbiota was investigated using Spearman's test and distance correlation. Results We observed that fungal microbiota is skewed in IBD, with an increased Basidiomycota/Ascomycota ratio, a decreased proportion of Saccharomyces cerevisiae and an increased proportion of Candida albicans compared with HS. We also identified disease-specific alterations in diversity, indicating that a Crohn's disease-specific gut environment may favour fungi at the expense of bacteria. The concomitant analysis of bacterial and fungal microbiota showed a dense and homogenous correlation network in HS but a dramatically unbalanced network in IBD, suggesting the existence of disease-specific inter-kingdom alterations. Conclusions Besides bacterial dysbiosis, our study identifies a distinct fungal microbiota dysbiosis in IBD characterised by alterations in biodiversity and composition. Moreover, we unravel here disease-specific inter-kingdom network alterations in IBD, suggesting that, beyond bacteria, fungi might also play a role in IBD pathogenesis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity.

            Fecal calprotectin (FC) is a promising biomarker for diagnosis of inflammatory bowel disease (IBD). However, the utility of FC for assessment of IBD activity has yet to be clearly demonstrated. The aim of our study was to evaluate the diagnostic accuracy of FC for differentiating between patients with active IBD and those in remission.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Disrupted Intestinal Microbiota and Intestinal Inflammation in Children with Cystic Fibrosis and Its Restoration with Lactobacillus GG: A Randomised Clinical Trial

              Background & Aims Intestinal inflammation is a hallmark of cystic fibrosis (CF). Administration of probiotics can reduce intestinal inflammation and the incidence of pulmonary exacerbations. We investigated the composition of intestinal microbiota in children with CF and analyzed its relationship with intestinal inflammation. We also investigated the microflora structure before and after Lactobacillus GG (LGG) administration in children with CF with and without antibiotic treatment. Methods The intestinal microbiota were analyzed by denaturing gradient gel electrophoresis (DGGE), real-time polymerase chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH). Intestinal inflammation was assessed by measuring fecal calprotectin (CLP) and rectal nitric oxide (rNO) production in children with CF as compared with healthy controls. We then carried out a small double-blind randomized clinical trial with LGG. Results Twenty-two children with CF children were enrolled in the study (median age, 7 years; range, 2–9 years). Fecal CLP and rNO levels were higher in children with CF than in healthy controls (184±146 µg/g vs. 52±46 µg/g; 18±15 vs. 2.6±1.2 µmol/L NO2 −, respectively; P<0.01). Compared with healthy controls, children with CF had significantly different intestinal microbial core structures. The levels of Eubacterium rectale, Bacteroides uniformis, Bacteroides vulgatus, Bifidobacterium adolescentis, Bifidobacterium catenulatum, and Faecalibacterium prausnitzii were reduced in children with CF. A similar but more extreme pattern was observed in children with CF who were taking antibiotics. LGG administration reduced fecal CLP and partially restored intestinal microbiota. There was a significant correlation between reduced microbial richness and intestinal inflammation. Conclusions CF causes qualitative and quantitative changes in intestinal microbiota, which may represent a novel therapeutic target in the treatment of CF. Administration of probiotics restored gut microbiota, supporting the efficacy of probiotics in reducing intestinal inflammation and pulmonary exacerbations. Trial Registration ClinicalTrials.gov NCT 01961661
                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                10 May 2019
                May 2019
                : 8
                : 5
                : 645
                Affiliations
                [1 ]Centre de Recherche Cardio-Thoracique de Bordeaux, INSERM, University Bordeaux, U1045, F-33000 Bordeaux, France; michael.fayon@ 123456chu-bordeaux.fr (M.F.); patrick.berger@ 123456u-bordeaux.fr (P.B.); laurence.delhaes@ 123456chu-bordeaux.fr (L.D.)
                [2 ]CRCM Pédiatrique, CHU Bordeaux, CIC 1401, F-33000 Bordeaux, France; haude.clouzeau@ 123456chu-bordeaux.fr (H.C.); stephanie.bui@ 123456chu-bordeaux.fr (S.B.); thierry.lamireau@ 123456chu-bordeaux.fr (T.L.)
                [3 ]Fédération Hospitalo-Universitaire FHU, ACRONIM, F-33000 Bordeaux, France; thomas.barnetche@ 123456chu-bordeaux.fr (T.B.); cecile.bebear@ 123456u-bordeaux.fr (C.B.); thierry.schaeverbeke@ 123456chu-bordeaux.fr (T.S.)
                [4 ]Bordeaux Bioinformatics Center, University Bordeaux, F-33000 Bordeaux, France; aurelien.barre@ 123456u-bordeaux.fr (A.B.); macha@ 123456labri.fr (M.N.)
                [5 ]Laboratoire Bordelais de Recherche en Informatique, CNRS, University Bordeaux, UMR 5800, F-33400 Talence, France
                [6 ]Service de Rhumatologie, CHU Bordeaux, F-33000 Bordeaux, France
                [7 ]INSERM, MRGM, University Bordeaux, U1211, F-33000 Bordeaux, France; christophe.hubert@ 123456u-bordeaux.fr
                [8 ]PGTB, University Bordeaux, F-33000 Bordeaux, France
                [9 ]BIOGECO, INRA, University Bordeaux, F-33610 Cestas, France; marie.massot@ 123456inra.fr
                [10 ]INRA—Bordeaux Aquitaine Centre, University Bordeaux, USC EA 3671, Infections Humaines à Mycoplasmes et à Chlamydiae, CHU Bordeaux, F-33000 Bordeaux, France; thomasbazin@ 123456club-internet.fr
                [11 ]BaRITOn, INSERM, University Bordeaux, UMR1053, CHU Bordeaux, F-33000 Bordeaux, France; philippe.lehours@ 123456chu-bordeaux.fr
                Author notes
                [* ]Correspondence: raphael.enaud@ 123456chu-bordeaux.fr (R.E.); katarzyna.hooks@ 123456u-bordeaux.fr (K.B.H.); Tel.: +33-556-799-824 (R.E.)
                [†]

                These authors contributed equally as co-first authors.

                Author information
                https://orcid.org/0000-0003-0687-4393
                https://orcid.org/0000-0003-3576-2518
                https://orcid.org/0000-0001-6059-577X
                https://orcid.org/0000-0002-5777-8492
                Article
                jcm-08-00645
                10.3390/jcm8050645
                6572243
                31083321
                25f8e727-9e47-4ef9-bead-89fe84724a7c
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 06 April 2019
                : 06 May 2019
                Categories
                Article

                cystic fibrosis,gut microbiota,intestinal inflammation,fecal calprotectin,dysbiosis index

                Comments

                Comment on this article